Scientific Advisory Board | Genomes to Natural Products Network (GNPN)

	Jon Clardy Harvard University	The Clardy laboratory focuses on biologically active small molecules, especially those from bacteria and fungi with an overall goal of understanding how small molecules control biological processes.
	Arthur Edison University of Georgia	The Edison lab uses metabolomics and natural products chemistry to understand the chemical basis of behavior. They leverage the extensive understanding of the C. elegans worm in their metabolomics studies to understand the role of small molecules in the C. elegans development and behavior.
	Jasper Rine University of California Berkeley	The research in Dr. Rine's lab is centered on the epigenetic mechanisms by which the information in a genome is expressed in a manner that is stable and heritable through cell division. Using the yeast Saccharomyces cerevisiae and the powerful genetic, genomic, and proteomic approaches that are so facile in this organism, the Rine Lab studies the nature of chromatin in specialized domains of the yeast genome, how it is assembled and modified, and how these modifications affect its expression, replication and repair.
	John Mulligan Good Therapeutics, Inc.	Dr. John Mulligan has over 20 years of experience in biotechnology industry during which he has (co)-founded 4 companies (Blue Heron Biotechnology, Cambrian Genomics, Glycostasis, and Good Therapeutics). He is currently the founder and CEO of Good Therapeutics, a start-up biotechnology company engineering proteins that, as the result of binding to a specific biomarker or metabolite, undergo activation of a therapeutic domain. Dr. Mulligan scientific expertise spans from drug discovery, genetics and synthetic biology.

Search form